A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.

about

A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.

Item

http://www.wikidata.org/entity/Q36094168

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A phase II clinical trial to i ...... G uptake in malignant lesions.

@ast

A phase II clinical trial to i ...... G uptake in malignant lesions.

@en

type

Item

label

A phase II clinical trial to i ...... G uptake in malignant lesions.

@ast

A phase II clinical trial to i ...... G uptake in malignant lesions.

@en

prefLabel

A phase II clinical trial to i ...... G uptake in malignant lesions.

@ast

A phase II clinical trial to i ...... G uptake in malignant lesions.

@en

P1476

A phase II clinical trial to i ...... G uptake in malignant lesions.

@en

P2093

Chang Ju Na

http://www.w3.org/2001/XMLSchema#string

Hee-Seung Bom

http://www.w3.org/2001/XMLSchema#string

Hwan-Jeong Jeong

http://www.w3.org/2001/XMLSchema#string

In-Jae Oh

http://www.w3.org/2001/XMLSchema#string

Jeonghun Kim

http://www.w3.org/2001/XMLSchema#string

Jung-Joon Min

http://www.w3.org/2001/XMLSchema#string

Myung-Hee Sohn

http://www.w3.org/2001/XMLSchema#string

Sehun Choi

http://www.w3.org/2001/XMLSchema#string

Seok Tae Lim

http://www.w3.org/2001/XMLSchema#string

Seong Young Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

The mechanisms of action of PPARs

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer.

Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting.

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

P2888

s13550-015-0128-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13550-015-0128-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Han-Jung Chae

P577

2015-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282245067

http://www.w3.org/2001/XMLSchema#string

P6179

1043403886

http://www.w3.org/2001/XMLSchema#string

P698

26408008

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4583556

http://www.w3.org/2001/XMLSchema#string